Flagship Private Wealth’s AstraZeneca AZN Stock Holding History

Flagship Private Wealth’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-60	Closed	-$6.2K	–	304
2020 Q4	$6.2K	Buy	+60	New	+$6.36K	0.01%	255

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Flagship Private Wealth's AZN Position: Q1 2021 in Review

Flagship Private Wealth sold out of AstraZeneca (AZN) in Q1 2021, closing a stake of 60 shares — an estimated $6.2K sold.

Flagship Private Wealth first reported a position in AZN in Q4 2020 and held it in 1 quarter. The position peaked at $6.2K in Q4 2020. 756 funds tracked by Wall St. Rank hold AZN as of Q1 2021.

Flagship Private Wealth reported no remaining AstraZeneca position as of Q1 2021 after selling out during the quarter.
Flagship Private Wealth sold 60 AstraZeneca shares in Q1 2021, an estimated $6.2K.
Flagship Private Wealth first reported a position in AstraZeneca in Q4 2020 and held it in 1 quarter.
Flagship Private Wealth's AstraZeneca position peaked at $6.2K in Q4 2020.
756 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2021.

Based on Flagship Private Wealth's 13F filing for Q1 2021, filed 9 Apr 2021.